Nicolai F.
- Country
- Germany
- Department
- Medizinische Klinik I (Onkologie, Pneumologie, Diabetologie)
Research Overview
- Phase III Evaluation of Elotuzumab with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant
- Phase III Randomized Study of CPX-351 Versus Standard Chemotherapy in Adults with Newly Diagnosed AML and Intermediate or Adverse Genetic Risk
- Phase III Non-Inferiority Trial of Lenalidomide, Bortezomib, Dexamethasone, and Isatuximab in Newly Diagnosed Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 110 of 391 partner sites.
Specializations
Hematologic Malignancies
Nicolai Faber is involved in clinical research in acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma, with attention to both newly diagnosed disease and mutation-defined subgroups. His work also extends to Hodgkin lymphoma, reflecting a strong focus on blood cancer treatment across different risk profiles and therapeutic settings.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Multiple myeloma
- Hodgkin lymphoma
His research landscape includes precision-oriented approaches in AML and supportive treatment concepts for MDS, alongside disease-control strategies in plasma cell disorders.
Targeted Therapy in Leukemia
His clinical interests include molecularly defined leukemia treatment, particularly in FLT3-mutated AML, IDH1- and IDH2-mutated disease, and NPM1-mutated AML. The trial portfolio also reflects interest in regimens for patients who are not eligible for intensive chemotherapy.
- FLT3-mutated AML
- IDH1 and IDH2 mutations
- NPM1-mutated AML
- Non-intensive treatment settings
This area places emphasis on mutation-directed treatment selection in leukemia and on expanding options for patients with limited tolerance for standard intensive approaches.
Thoracic Oncology
Nicolai Faber is also active in lung cancer research, including locally advanced or metastatic non-small cell lung cancer and small-cell lung cancer. His work spans first-line treatment questions and care for patients with poor performance status.
- Non-small cell lung cancer
- Small-cell lung cancer
- KRAS G12C-mutated disease
- Poor performance status
These studies reflect a therapeutic interest in advanced thoracic malignancies and biomarker-informed treatment pathways.
Gastrointestinal Oncology
His research includes colon cancer and rectal cancer, with attention to stage II disease and postoperative treatment decisions. This area addresses recurrence risk assessment and adjuvant treatment considerations in colorectal malignancies.
- Colon cancer stage II
- Rectal cancer stage II
- Adjuvant therapy
- ctDNA-guided treatment
His involvement in this field highlights an interest in refining treatment selection for localized colorectal cancer.
Supportive and Palliative Care
In addition to disease-directed oncology, Nicolai Faber is involved in palliative care, quality of life, and symptom-focused research. His portfolio includes studies addressing symptom burden in oncologic patients and treatment of anemia in lower-risk MDS.
- Palliative oncology
- Quality of life
- Symptom burden
- Anemia in myelodysplastic syndrome
This area also includes supportive care strategies for patients with transfusion-independent anemia and broader symptom management in advanced cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.